FDA OK's Lilly/BI dual mechanism diabetes drug Glyxambi
This article was originally published in Scrip
Executive Summary
Lilly and Boehringer Ingelheim won the FDA's blessing on 2 February to market Glyxambi (empagliflozin/linagliptin) – the first and only diabetes treatment in the US to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet taken in the morning.